JNJ-63823539

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameJNJ-63823539

Drug Alias NameTNF-alpha/IL-17a bispecific antibodyJNJ-63823539

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin 17A inhibitorsTumor necrosis factor α inhibitors

TargetsInterleukin 17ATumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson Innovative Medicine

Inactive CompaniesN/A

Active IndicationsArthritis, Rheumatoid

Inactive IndicationsN/A

Other Information

ATC CodeN/A